NYMOX Provides Shareholder Update
September 10, 2021 09:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide an update on the Company's progress with its BPH...
Nymox Announces Date for Fexapotide Filing
May 06, 2021 13:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it will be filing for marketing approval of...
Nymox Announces $8,000,000 Private Placement
April 28, 2021 08:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today announced it has entered into a definitive agreement with...
Nymox Provides New Update on Regulatory Activities
March 29, 2021 09:20 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide the latest update on the Company's regulatory filing preparation...
Nymox Provides Update on Regulatory Filing Activities
November 16, 2020 10:00 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide...
Nymox Announces $9 Million Registered Direct Offering
August 12, 2020 09:24 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited...
NYMOX Provides Current Update on Key Company Developments
July 28, 2020 09:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report current updates on the Company's most important ongoing developments....
Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement
June 19, 2020 09:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., June 19, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is very pleased to report that key steps in its regulatory submission preparations have...
Nymox Announces Important New Patent Developments
April 21, 2020 09:45 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the recent allowances of 4 new different US and international...
Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology
February 24, 2020 09:30 ET
|
Nymox Pharmaceutical Corporation
HASBROUCK HEIGHTS, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that a new peer review report was published today in the World...